220 related articles for article (PubMed ID: 3470306)
1. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
Weintraub MS; Eisenberg S; Breslow JL
J Clin Invest; 1987 Apr; 79(4):1110-9. PubMed ID: 3470306
[TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Houlston R; Quiney J; Watts GF; Lewis B
J R Soc Med; 1988 May; 81(5):274-6. PubMed ID: 3164409
[TBL] [Abstract][Full Text] [Related]
3. Effect of gemfibrozil on serum lipid levels.
Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
Artery; 1980; 7(3):224-31. PubMed ID: 7008748
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
[No Abstract] [Full Text] [Related]
5. Vitamin A loading--an indicator of post-prandial lipoprotein clearance in healthy and hypertriglyceridemic subjects.
Rassin T; Liron M; Rubinstein A; Arad J; Weintraub M
Isr J Med Sci; 1992 Oct; 28(10):706-10. PubMed ID: 1399499
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil plus cholestyramine in familial hypercholesterolaemia.
Jones AF; Hughes EA; Cramb R
Lancet; 1988 Apr; 1(8588):776. PubMed ID: 2895309
[No Abstract] [Full Text] [Related]
7. Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku K; Gartside PS; Hynd BA; Kashyap ML
J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and management of lipoprotein disorders.
Schaefer EJ; Levy RI
N Engl J Med; 1985 May; 312(20):1300-10. PubMed ID: 3887163
[No Abstract] [Full Text] [Related]
9. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
[No Abstract] [Full Text] [Related]
10. Disturbances in dietary fat metabolism and their role in the development of atherosclerosis.
Weintraub M; Charach G; Grosskopf I
Biomed Pharmacother; 1997; 51(8):311-3. PubMed ID: 9436521
[TBL] [Abstract][Full Text] [Related]
11. Role of basal triglyceride and high density lipoprotein in determination of postprandial lipid and lipoprotein responses.
O'Meara NM; Lewis GF; Cabana VG; Iverius PH; Getz GS; Polonsky KS
J Clin Endocrinol Metab; 1992 Aug; 75(2):465-71. PubMed ID: 1639947
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia.
Föger B; Drexel H; Hopferwieser T; Miesenböck G; Ritsch A; Lechleitner M; Tröbinger G; Patsch JR
Clin Investig; 1994 Mar; 72(4):294-301. PubMed ID: 8043977
[TBL] [Abstract][Full Text] [Related]
13. Gemfibrozil--a new lipid lowering agent.
Nash DT
J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
[TBL] [Abstract][Full Text] [Related]
14. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of hyperlipidemia.
Gotto AM; Jones PH; Scott LW
Dis Mon; 1986 May; 32(5):245-311. PubMed ID: 3519132
[No Abstract] [Full Text] [Related]
16. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism.
Reznik Y; Pousse P; Herrou M; Morello R; Mahoudeau J; Drosdowsky MA; Fradin S
Metabolism; 1996 Jan; 45(1):63-71. PubMed ID: 8544779
[TBL] [Abstract][Full Text] [Related]
17. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus.
Syvänne M; Vuorinen-Markkola H; Hilden H; Taskinen MR
Arterioscler Thromb; 1993 Feb; 13(2):286-95. PubMed ID: 8427863
[TBL] [Abstract][Full Text] [Related]
18. Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease.
Kuo PT; Wilson AC; Kostis JB; Moreyra AB; Dodge HT
Am Heart J; 1988 Jul; 116(1 Pt 1):85-90. PubMed ID: 3164977
[TBL] [Abstract][Full Text] [Related]
19. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities.
Lewis GF; O'Meara NM; Soltys PA; Blackman JD; Iverius PH; Pugh WL; Getz GS; Polonsky KS
J Clin Endocrinol Metab; 1991 Apr; 72(4):934-44. PubMed ID: 2005221
[TBL] [Abstract][Full Text] [Related]
20. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.
Simo IE; Yakichuk JA; Ooi TC
Atherosclerosis; 1993 Apr; 100(1):55-64. PubMed ID: 8318063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
